In short
Clinical trials are investigating LY3537021 in adults with cancer who have nausea and vomiting caused by chemotherapy. These studies look at how well LY3537021 works, along with standard anti-nausea treatments, and whether it is safe and effective in this setting.
Key points
- Clinical trials of LY3537021 are studying nausea and vomiting caused by chemotherapy in adults with cancer. The listed trial is a Phase 2 study, so it is looking at early signs of benefit while also checking safety. Researchers are comparing LY3537021 with placebo, both given with other anti-nausea treatments. The main outcome is complete response in the delayed phase, meaning no vomiting and no rescue medicine. The trial is authorised and plans to include 205 participants.
Trial overview
The clinical trial with ID NCT07169851 is studying LY3537021 for nausea and vomiting caused by chemotherapy in adults with cancer. The study is authorised and is planned as a Phase 2 interventional trial. It plans to enroll 205 people.
Who can join
This trial is for adults with cancer who are receiving chemotherapy and have nausea and vomiting related to that treatment. The source data does not list more detailed entry rules, so final participation depends on the study team’s screening checks.
What is being measured
The main outcome is complete response in the delayed phase of chemotherapy-induced nausea and vomiting. In this study, complete response means no vomiting and no rescue medication. Rescue medication is extra medicine used if symptoms are not fully controlled.
Treatment groups in the study
The study compares LY3537021 plus other anti-nausea treatments with placebo plus the same background anti-nausea treatments. The listed background medicines include ondansetron, aprepitant, palonosetron, granisetron, dexamethasone, and 0.9% sodium chloride. A placebo is a look-alike treatment used for comparison that does not contain the study drug.
Study design and phase
This is an interventional study, which means researchers give a treatment and then measure the results. It is a Phase 2 trial, which usually looks at early signs of how well a treatment works and continues to check safety. The trial is focused on patients with cancer who need help preventing or reducing chemotherapy-related nausea and vomiting.
Why this trial matters for patients
Chemotherapy-related nausea and vomiting can make cancer treatment harder to tolerate, so studies like this try to find better ways to control symptoms. The delayed phase is important because symptoms can continue after treatment ends, not just right away. By measuring complete response, researchers can see whether LY3537021 helps patients avoid vomiting and avoid needing extra medicine.